← Issue №14/ week of Oct 4, 2026/Colorectal

Trends and Survival Outcomes of Adjuvant Chemotherapy in Low-Risk Stage II Colon Cancer: A National Cancer Database Analysis.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal retrospective · n=7,204 · Sep 30, 2026 · Dis Colon Rectum · IF 3.5

Trends and Survival Outcomes of Adjuvant Chemotherapy in Low-Risk Stage II Colon Cancer: A National Cancer Database Analysis.

New evidenceepidemiologycolorectal cancerhealth services
Clinical takeawayDo not administer adjuvant chemotherapy to patients with low-risk Stage II colon cancer unless they meet guideline-defined high-risk criteria.
What it foundAdjuvant chemotherapy in low-risk Stage II colon cancer showed no survival benefit after adjustment compared to standard of care (HR 0.998; 95% CI: 0.709-1.404).
ContextChallenges the practice of using adjuvant chemotherapy in low-risk Stage II colon cancer, reinforcing current guidelines that limit its use to high-risk patients. This conclusion is based on a retrospective analysis with limitations, including lack of disease-specific survival data.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Kahana N … Emile SH · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues